Doctors Recommend A New Complex Cancer Treatment – Part 1 of 3
Doctors Recommend A New Complex Cancer Treatment. Women with quarrelsome breast cancer who receive combination targeted therapy with chemotherapy prior to surgery have a a little improved chance of staying cancer-free, researchers say. However, the improvement was not statistically significant and the jury is still out on combination treatment, said lead researcher Dr Martine Piccart-Gebhart, chair of the Breast International Group, in Brussels. “I don’t reflect that tomorrow we should switch to a new standard of care.
Piccart-Gebhart presented her findings Wednesday at the 2013 San Antonio Breast Cancer Symposium, alongside other scrutinization that investigated ways to improve treatment for women with HER2-positive breast cancer. This aggressive form of cancer is linked to a genetic irregularity. Other researchers reported the following. The targeted knock out trastuzumab (Herceptin) worked better in HER2-positive breast cancer tumors containing high levels of immune cells.
A combination of the chemotherapy drugs docetaxel and carboplatin with Herceptin appeared to be the best postsurgery healing option. Overall, the studies were good news for women with HER2-positive breast cancer, which used to be one of the most fatal forms of the disease. Researchers reported long-term survival rates higher than 90 percent for women treated using the targeted analysis drugs. “That tells you these treatments are very, very effective,” Piccart-Gebhart said.
Piccart-Gebhart’s combo targeted group therapy trial is evaluating whether the HER2-targeted drugs Herceptin and lapatinib (Tykerb) work better when combined on top of standard chemotherapy. The trial involved 455 patients with HER2-positive soul cancer with tumors larger than 2 centimeters. The women were given chemotherapy prior to surgery along with either Herceptin, Tykerb, or a combination of the two targeted drugs. They also were treated after surgery with whichever targeted cure they had been receiving.